Sunshine Biopharma INC 8-K filings

Sunshine Biopharma Inc. announced an adjustment to its Series B Warrants' exercise price, lowering it to $1.2202 due to recent at-the-market stock sales.

Sunshine Biopharma Inc. has entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. to sell up to $4 million in common stock.

Sunshine Biopharma Inc. and its subsidiary Nora Pharma Inc. have entered into a settlement agreement with former Nora President Malek Chamoun, resolving a dispute for CAD$1,500,000.

Sunshine Biopharma CEO Dr. Steve N. Slilaty approved via written consent the issuance of shares and warrant adjustments related to the May 2026 public offering.

Sunshine Biopharma Inc. announced the pricing of a public offering expected to raise approximately $6.0 million before expenses, consisting of units with common stock and warrants.

Sunshine Biopharma Inc. announced its fiscal year 2025 financial results, reporting a 4.1% increase in revenue to $36.3 million and the launch of nine new generic drugs.

Sunshine Biopharma Inc. announced the immediate resignation of Dr. Abderrazzak Merzouki as Chief Operating Officer, effective February 5, 2026.

Sunshine Biopharma Inc. announced the results of its annual stockholders meeting, confirming director re-elections, auditor ratification, and an increase in its equity incentive plan shares.

Sunshine Biopharma Inc. has dismissed Bush & Associates CPA LLC and appointed M&K CPAS, PLLC as its new independent registered public accounting firm, effective September 24, 2025.

Sunshine Biopharma announces an 18% increase in revenue for the first quarter of 2025, alongside the launch of new generic drugs and progress in cancer research.

Sunshine Biopharma Inc. has successfully closed a registered direct offering, raising $2.46 million through the sale of common stock and pre-funded warrants.

Sunshine Biopharma announces a 45% increase in revenue, reaching $34.9 million for fiscal year 2024, alongside advancements in drug development and regulatory approvals.

Sunshine Biopharma has appointed Michel Roy as its new Chief Commercial Officer, effective immediately, to lead commercial strategy and drive market expansion.

Sunshine Biopharma held its annual stockholder meeting on December 10, 2024, where directors were elected and the appointment of an independent accounting firm was ratified.

Sunshine Biopharma announced a 42% increase in third-quarter revenue compared to the same period last year, driven by new product launches and expanded marketing efforts.

Sunshine Biopharma has amended employment agreements with its CEO, CFO, and COO, effective January 1, 2024, outlining their roles, compensation, and severance terms.

Sunshine Biopharma has regained compliance with Nasdaq's bid price rule but will be subject to a one-year monitoring period.

Sunshine Biopharma announced a 67% increase in second-quarter revenue and a 61% increase in year-to-date revenue, alongside a significant reduction in net losses.

Sunshine Biopharma has executed a 1-for-20 reverse stock split, effective August 7, 2024, to consolidate its common stock.

Sunshine Biopharma's majority shareholder approved a reverse stock split of up to 60-for-1, effective 20 days after the information statement is mailed to shareholders.

Sunshine Biopharma has received an extension from Nasdaq until August 26, 2024, to regain compliance with the minimum bid price requirement.

Sunshine Biopharma reports that all Series A Warrants issued on February 15, 2024, have been exercised as of June 11, 2024.

Sunshine Biopharma received a delisting notification from Nasdaq due to concerns about substantial shareholder dilution caused by the terms of its Series A warrants.

Sunshine Biopharma announced a 54% increase in first-quarter revenue compared to the same period last year, driven by new product launches and expanded marketing efforts.

Sunshine Biopharma has replaced its independent registered public accounting firm with Bush & Associates, effective May 7, 2024.

Sunshine Biopharma has dismissed its auditor, BF Borgers CPA, PC, after the SEC issued a permanent ban against the firm.

Sunshine Biopharma has executed a 1-for-100 reverse stock split, effective April 17, 2024, to consolidate its outstanding shares.

Sunshine Biopharma's 2023 financial results show significant sales growth and a substantial reduction in net loss per share compared to the previous year.

Sunshine Biopharma's CEO, Dr. Steve Slilaty, purchased 100,000 shares of Series B Preferred Stock for $10,000 and approved a reverse stock split to regain Nasdaq compliance.

Sunshine Biopharma is appealing Nasdaq's decision to delist its stock after it traded below $0.10 for ten consecutive days, while also planning a 40-for-1 reverse stock split to regain compliance.